FLOW Trial: Semaglutide 1.0mg Reduces Kidney, Cardiovascular Risks by 24% in Diabetic CKD Patients

May 24, 2024, 10:35 AM

The FLOW trial has shown that semaglutide, a GLP-1 receptor agonist, significantly reduces the risk of serious kidney outcomes, major cardiovascular events, and death among patients with type 2 diabetes and chronic kidney disease (CKD). The trial, which involved 3,533 participants over approximately three years, was stopped early due to its efficacy. Results indicated a 24% reduction in kidney disease progression and cardiovascular and kidney death. The study, published in NEJM, highlighted that a weekly 1.0mg dose of semaglutide was effective.